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Abstract: Plakophilin-2 (PKP2) is the most frequently mutated desmosomal gene in arrhythmogenic
cardiomyopathy (ACM), a disease characterized by structural and electrical alterations predominantly
affecting the right ventricular myocardium. Notably, ACM cases without overt structural alterations
are frequently reported, mainly in the early phases of the disease. Recently, the PKP2 p.S183N
mutation was found in a patient affected by Brugada syndrome (BS), an inherited arrhythmic
channelopathy most commonly caused by sodium channel gene mutations. We here describe a case
of a patient carrier of the same BS-related PKP2 p.S183N mutation but with a clear diagnosis of ACM.
Specifically, we report how clinical and molecular investigations can be integrated for diagnostic
purposes, distinguishing between ACM and BS, which are increasingly recognized as syndromes
with clinical and genetic overlaps. This observation is fundamentally relevant in redefining the role of
genetics in the approach to the arrhythmic patient, progressing beyond the concept of “one mutation,
one disease”, and raising concerns about the most appropriate approach to patients affected by
structural/electrical cardiomyopathy. The merging of genetics, electroanatomical mapping, and tissue
and cell characterization summarized in our patient seems to be the most complete diagnostic
algorithm, favoring a reliable diagnosis.
Keywords: Brugada syndrome; arrhythmogenic cardiomyopathy; PKP2; endomyocardial biopsy;
cardiac mesenchymal stromal cells; mutation; diagnosis; functional studies
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1. Introduction
Arrhythmogenic cardiomyopathy (ACM) and Brugada syndrome (BS) are inherited arrhythmia
diseases that lead to sudden cardiac death. ACM hearts are characterized by ventricular structural
alterations showing a progressive fibro-fatty infiltration associated with ventricular mechanical and
electrical dysfunction. Mutations in different genes, mainly desmosomal, have been implicated in
ACM pathogenesis, and most reside in the gene coding for Plakophilin-2 (PKP2) [1]. BS is a genetic
channelopathy characterized by ST-segment elevation of coved morphology in right precordial
electrocardiogram (ECG) leads, increased risk of ventricular tachycardia, and fibrillation in the absence
of cardiac structural disease [2]. Mutations in the SCN5A gene, coding for the main cardiac sodium
channel, account for approximately 20%–25% of genotype-positive subjects, and overall only 25%–30%
of BS patients have a known genetic defect [3].
The intercalated disc hosts a common protein interacting network, the connexome, that includes
molecules of the desmosome and the voltage-gated sodium channel (VGSC) complex. According to
this, if the molecular substrates (desmosomes and VGSC) are part of a common network, BS and
ACM should also share some common features. It is estimated that as many as 70% of the mutations
linked to familial ACM are in the gene coding for PKP2, a 98 kDa desmosomal protein that interacts
with plakoglobin, desmoplakin, and the desmosomal cadherins via its amino-terminal domain [4].
Mutations in PKP2 may therefore destabilize the desmosome and result in arrhythmias and structural
alteration simultaneously.
Although a general phenotypic distinction exists between the two pathologies, imaging and
histopathological data support the notion that BS is not purely arrhythmogenic but includes, in some
cases, structural anomalies [5]. Molecular data demonstrated that arrhythmias in ACM are consequent
not only to tissue alterations but also to changes in the intercalated disc subdomain, including
desmosomes, connexins, and sodium channels [6]. Additionally, from a genetic point of view,
overlapping between ACM and BS was reported. In the continuing search for new causative gene
variants in genetically-negative patients, researchers identified SCN5A mutations in some ACM
patients [7], and PKP2 mutations were associated with BS [8]. The two diseases seem to overlap
in more than one aspect and a deeper analysis of every patient is required. Herein, we present
a patient diagnosed with ACM, in whom a PKP2 mutation, known to be causative for BS, was found.
In particular, we report how molecular data (based on the use of cardiac mesenchymal stromal cells
(C-MSCs) as an ACM in vitro model [9]) could confirm the clinical correct diagnosis.
2. Materials and Methods
2.1. Ethical Statement
This study complied with the Declaration of Helsinki and was approved by the Centro Cardiologico
Monzino-IRCCS Ethic Committee. Written consent was signed by participating patients.
2.2. Genotype Analysis
DNA was extracted from blood. Next-generation sequencing was performed (Illumina NextSeq,
San Diego, CA, USA) with the TruSight™ Cardio Sequencing Kit. The alignment of sequence reads to
reference human genome (GRCh37/hg19) was performed using GATK software (the GATK software is
available as an open-source framework on The Broad Institute’s website). Variants in DSC2, DSG2,
DSP, PKP2, JUP, TMEM43, RYR2, PLN, SCN5A, and LMNA were filtered with Wannovar and classified
according to [10]. Pathogenic mutations were confirmed by Sanger sequencing.
2.3. Cardiac Mesenchymal Stromal Cell isolation
Cells were obtained from patient endomyocardial biopsies, as previously described [11].
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2.4. Oil Red O Staining
C-MSCs were cultured in adipogenic medium (as in [11]) for three days, fixed with 4%
paraformaldehyde (PFA) and neutral lipids were visualized by Oil Red O (ORO) staining. Pictures were
captured with an Axiovert microscope (Zeiss, Oberkochen, Germany) and quantified with AxioVision
Rel.4.8. (Zeiss, Oberkochen, Germany).
2.5. Real-Time PCR
Total RNA was extracted using Trizol (ThermoFisher Scientific, Waltham, MS, USA) and reverse
transcribed with SuperscriptIII First-Strand Synthesis SuperMix (Invitrogen, Carlsbad, CA, USA).
Quantitative real time-polymerase chain reaction (qRT-PCR) was performed in duplicate using 10 ng
of cDNA, the iTaq Universal SYBR Green Supermix (Bio-Rad, Hercules, California, United States) and
the following primers:
PLIN1-FW: 5′-CATTGAGAAGGTGGTGGAGTA-3′
PLIN1-REV: 5′-CTTGGCCTTGGGAGACTT-3′
PPARγ-FW: 5′-ACATAAAGTCCTTCCCGCTGACCA-3′
PPARγ-REV: 5′-AAACTGGCAGCCCTGAAAGATGC -3′
GAPDH- FW: 5′- ATGTTCGTCATGGGTGTGAA-3′
GAPDH- REV: 5′- GTCTTCTGGGTGGCAGTGAT-3′
2.6. Western Blot Analysis
C-MSC proteins were separated and transferred as in [9]. The membrane was incubated with
primary antibodies against Plakophilin-2 (PKP2; BD Transduction Laboratories; Franklin Lakes, NJ,
USA; 1:500), and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology;
Dallas, TX, USA; 1:2000). After incubation with proper secondary chemiluminescent antibodies,
the signal was acquired and quantified using Alliance software (version 1D MAX, UVITEC, Cambridge,
England, UK).
2.7. Immunofluorescence
After fixation with 4% paraformaldehyde (PFA), cells were incubated with primary antibodies
against plakoglobin (PG; Sigma-Aldrich; St. Louis, Missouri, United States; 1:100) and peroxisome
proliferator-activated receptorγ (PPAR-γ; Santa Cruz Biotechnology; Dallas, TX, USA; 1:100). Cells were
incubated with the appropriate Alexa 488-conjugated secondary antibody. Cell nuclei were stained with
Hoechst 33342. Pictures were acquired with an Apotome microscope (Zeiss, Oberkochen, Germany).
The positive cell number was normalized to the nuclei number.
2.8. Statistical Analysis
Statistics were performed using GraphPad Prism software (version 5 San Diego, CA, USA).
Comparison between groups was performed using two-tailed Student’s t-tests. Results were considered
statistically significant for p < 0.05.
3. Results
3.1. Clinical Data
A 41-year-old man, known for a history of premature ventricular complexes (PVCs) since 2009,
with no prior history of cardiac diseases and no family history of sudden death, was admitted to our
department in 2016. A basal ECG showed sinus bradycardia, nonspecific repolarization abnormalities.
Previous echocardiogram and cardiac magnetic resonance (MRI) showed cardiac biventricular
dysfunction with enlargement of the right-side chambers. No areas of late gadolinium enhancement
or lipomatous infiltration were evident. A two-dimensional echocardiogram at admission showed
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biventricular dilation (left ventricular end-diastolic volume (LVEDV), 80 mL/m2; right ventricular
end-diastolic basal diameter, 45 mm) and mild biventricular dysfunction (left ventricular ejection
fraction (LVEF), 50%; tricuspid annular plane systolic excursion (TAPSE), 19 mm; right ventricular
fractional area change (RVFAC), 21%), with no relevant valvular abnormalities. A cardiac MRI was
performed again during hospitalization (Figure 1A) and showed biventricular dilation (LVEDV,
125.8 mL/m2; right ventricular end-diastolic volume (RVEDV), 171 mL/m2), mild biventricular
dysfunction (LVEF, 50%; right ventricular ejection fraction (RVEF), 37%), right ventricle diffuse
hypokinesia with basal right ventricle outflow tract (RVOT) akinesia, and areas suspicious for adipose
infiltration at the apex of the right ventricle and in the basal segments of the anterior wall of the left
ventricle. A Holter ECG showed 3500 premature ventricular contractions (PVCs), with 223 couplets
and 13 triplets. No sustained ventricular arrhythmias were evoked by programmed stimulation
(electrophysiological study (EPS)). During the EPS, three different PVC morphologies were recorded:
one with RVOT morphology and two with left-side origins. According to the substrate analysis and
the RVOT morphology of the PVC, pace mapping was performed, and finally radiofrequency was
applied to ablate the origin of the PVC. Electroanatomical mapping (Figure 1B) showed unipolar
low-voltage areas in the RVOT, which were suggestive of epicardial scarring [12]. In the same area,
an endocardial cardiac biopsy was performed, which was sent for histological analysis. The results
confirmed the tissue pattern was compatible with the diagnosis of ACM (fibro-fatty substitution,
Figure 1C). The ACM diagnosis was based on one major MRI criterion, one minor arrhythmia criterion,
and one minor wall-tissue characterization criterion [13]. An implantable cardioverter-defibrillator
(ICD) was therefore implanted. The patient was then discharged with sotalol therapy. The genetic
screening by next-generation sequencing of the genes DSC2, DSG2, DSP, PKP2, JUP, TMEM43, RYR2,
PLN, and LMNA revealed the presence of the PKP2 gene in exon 3 of the c.548G>A mutation that
causes p.S183N substitution. This rare variant was previously described as causative of BS [8], but has
never been associated with ACM. This result raised the suspicion of a misdiagnosis and the patient
was recalled to perform an ajmaline test. No type 1 Brugada ECG pattern was evoked (Figure 1D) and
the diagnosis of BS was ruled out. During three years of follow-up, no recurrent arrhythmias were
evident from remote monitoring or ambulatory visits.
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Figure 1. Clinical data are not compatible with BS phenotypes. (A) Cardiac magnetic resonance
showing biventricular dilation and areas suspicious for adipose infiltration at the apex of the right
ventricle (RV). (B) Bipolar (left) and unipolar (right) electroanatomical mapping of the RV of the patient.
Unipolar voltage mapping showed low-voltage areas in the RV outflow tract. (C) Endomyocardial
biopsy showing fibro-fatty substitution, compatible with arrhythmogenic cardiomyopathy diagnosis.
(D) 1 mg/kg of ajmaline was administered to the patient over 10 min followed by 5 min of wash-out
observation: no type-1 BS electrocardiographic pattern was induced. BS, Brugada syndrome.
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A 28-year-old athlete with a clinical and genetic diagnosis of BS (heterozygous c.4867C>T,
p.Arg1623X in the SCN5A gene), who previously underwent cardiac biopsy to rule out ACM, was used
for comparative analysis.
3.2. Molecular Data
C-MSCs were isolated from endomyocardial biopsies obtained from the ACM and BS patients
and used to study their molecular phenotypes. As reported in the literature, PKP2 is expressed less in
C-MSC isolated from ACM patients than in healthy controls [9]. Accordingly, the level of PKP2 in the
ACM patient’s C-MSCs was lower than that of the C-MSCs obtained from the BS patient (Figure 2A).
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We then investigated the capability of ACM and BS C-MSCs to accumulate lipids in adipogenic
conditions. We found that ACM C-MSCs showed higher expressions of adipogenic genes such as PLIN1
and PPARγ and were more prone to accumulate neutral lipids than C-MSCs in the BS patient (Figure 2B,
C). It has been reported that switching to adipogenic fate in ACM cases is linked to alterations in the
Wnt/β-catenin pathway and PG nuclear translocation [9]. ACM C-MSCs showed a larger number
of PG-positive nuclei than BS C-MSCs as well as more PPARγ nuclear localization, as previously
observed [14] when cultured in adipogenic medium (Figure 2D).
4. Discussion
Defining the meaning and the correct genotype–phenotype association of potentially pathogenic
variants is an extreme challenge, even in the presence of in vitro functional validation. The effect of
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a mutation could be modified by various factors, such as the expression of the allele in different cell
types, the patient’s genetic background (which may include phenotype-modifier variants), and the
compensation of other mechanisms, including epigenetic and environmental mechanisms.
To date, eight variants in the PKP2 gene—the most prevalent gene associated with ACM—have
been found in BS patients, either alone or in combination with other gene variants [15–17]. In vitro
studies in HL-1 cells of four of these variants showed sodium current alterations and a PKP2-dependent
defect in sodium channel trafficking via microtubules to the intercalated disc [17]. We hypothesized
that these mechanisms are shared between BS and ACM based on both also occurring in induced
pluripotent stem cell (iPSC)-derived cardiomyocytes from a patient carrier of an ACM-associated PKP2
mutation and in PKP2-deficient mouse cardiomyocytes.
However, the present report describes one of the PKP2 BS-related mutations (p.S183N) associated
with an ACM phenotype.
A limitation of the previous study [8] was the impossibility of determining whether the reported PKP2
mutation occurred in the context of additional genetic differences, other than in the four most common
genes associated with BS. Indeed, there is a large number of known proteins that can directly or indirectly
affect the sodium current. The clinical characteristics of the patient carrier of the p.S183N mutation were not
definitely diagnostic of BS, since the type 1 ECG pattern was observed during a febrile episode and not
confirmed by a provocative test [8]. This finding could therefore be an unspecific sign of BS-like ECG [18].
Further clinical investigation should be performed to exclude the presence of ACM in the concealed phase
mimicking BS. The ClinGen consortium has reclassified most of the genes described as potentially linked to
BS as not having sufficient evidence to support their causality for BS [19]. Thus, genetic testing of these
genes may lead to incorrect interpretation of variants.
Despite being recognized as functionally relevant [8], rare (minor allele frequency (MAF) = 0.0082
according to the Genome Aggregation Database) and relatively conserved among species, the available
evidence cannot rule out a low pathogenicity effect of the PKP2 p.S183N variant alone. It may represent
a phenotypic modulator with no clear deterministic cut-off through either BS or ACM phenotypes.
Few rare causes of ACM have not been excluded by our genetic tests and known genetic causes of
ACM only support about 50% of affected patients.
In conclusion, PKP2 variants in BS cases should be interpreted carefully. The complex
decision-making network may benefit from additional functional analyses in cells that carry the
whole genetic background of a patient, as in this present report, accompanied by a careful clinical and
genetic interpretation in a family context.
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